
Novavax Inc (NASDAQ:NVAX) is trading higher Monday after the company submitted a request to the U.S Food and Drug Administration for Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373.
Novavax's submission includes the results from two large pivotal clinical trials which demonstrated approximately 90% overall efficacy. In both trials, the vaccine demonstrated efficacy with a reassuring safety profile, according to the company.